A detailed history of Oak Asset Management, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Oak Asset Management, LLC holds 1,635 shares of REGN stock, worth $1.17 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
1,635
Previous 1,785 8.4%
Holding current value
$1.17 Million
Previous $1.88 Million 8.42%
% of portfolio
0.61%
Previous 0.69%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

SELL
$1024.09 - $1201.76 $153,613 - $180,264
-150 Reduced 8.4%
1,635 $1.72 Million
Q2 2024

Jul 12, 2024

SELL
$883.2 - $1071.19 $22,080 - $26,779
-25 Reduced 1.38%
1,785 $1.88 Million
Q1 2024

Apr 17, 2024

SELL
$902.69 - $993.35 $45,134 - $49,667
-50 Reduced 2.69%
1,810 $1.74 Million
Q4 2023

Jan 23, 2024

SELL
$775.18 - $881.7 $19,379 - $22,042
-25 Reduced 1.33%
1,860 $1.63 Million
Q4 2022

Feb 07, 2023

SELL
$705.89 - $766.39 $289,414 - $314,219
-410 Reduced 17.86%
1,885 $1.36 Million
Q3 2022

Oct 18, 2022

BUY
$573.97 - $724.32 $1.32 Million - $1.66 Million
2,295 New
2,295 $1.58 Million
Q2 2022

Jul 15, 2022

SELL
$548.35 - $738.84 $1.26 Million - $1.7 Million
-2,295 Closed
0 $0
Q2 2021

Jul 14, 2021

BUY
$472.8 - $558.54 $1.09 Million - $1.28 Million
2,295 New
2,295 $1.28 Million
Q1 2021

Apr 27, 2021

SELL
$446.73 - $548.2 $1.03 Million - $1.26 Million
-2,295 Closed
0 $0
Q2 2019

Jul 25, 2019

BUY
$299.6 - $414.82 $687,582 - $952,011
2,295 New
2,295 $681,000
Q1 2018

Apr 23, 2018

SELL
$315.82 - $393.78 $235,285 - $293,366
-745 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$358.63 - $469.95 $267,179 - $350,112
745
745 $280,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.6B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Oak Asset Management, LLC Portfolio

Follow Oak Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oak Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Oak Asset Management, LLC with notifications on news.